Cargando…

Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study

INTRODUCTION: Impulse control disorders (ICDs) have been described as a side effect of dopamine agonists (DAs) in neurological as well as endocrine conditions. Few studies have evaluated the neuropsychological effect of DAs in hyperprolactinemic patients, and these have reported a relationship betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beccuti, G., Guaraldi, F., Natta, G., Cambria, V., Prencipe, N., Cicolin, A., Montanaro, E., Lopiano, L., Ghigo, E., Zibetti, M., Grottoli, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285332/ https://www.ncbi.nlm.nih.gov/pubmed/33314003 http://dx.doi.org/10.1007/s40618-020-01478-0

Ejemplares similares

First but not second postoperative day growth hormone assessments as early predictive tests for long-term acromegaly persistence
por: Cambria, V., et al.
Publicado: (2021)

Impulse control disorders and dopamine agonists
por: Martins, D., et al.
Publicado: (2021)

Development and Internal Validation of a Predictive Model for Adult GH Deficiency Prior to Stimulation Tests
por: Bioletto, Fabio, et al.
Publicado: (2021)

Dopamine Agonists and Impulse Control Disorders: A Complex Association
por: Grall-Bronnec, Marie, et al.
Publicado: (2017)

MON-293 The Prevalence of Impulse Control Disorders in Patients with Acromegaly and Prolactinomas Treated with Dopamine Agonists
por: Ozkaya, Hande Mefkure, et al.
Publicado: (2020)

Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view
por: Berton, A. M., et al.
Publicado: (2020)

Hypothalamic-Pituitary Autoimmunity and Traumatic Brain Injury
por: Guaraldi, Federica, et al.
Publicado: (2015)

Impulsivities and Parkinson's Disease: Delay Aversion Is Not Worsened by Deep Brain Stimulation of the Subthalamic Nucleus
por: Torta, Diana M. E., et al.
Publicado: (2012)

Traumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment
por: Gasco, Valentina, et al.
Publicado: (2021)

Onset of Covid-19 with impaired consciousness and ataxia: a case report
por: Balestrino, R., et al.
Publicado: (2020)

Pisa Syndrome in Parkinson's Disease Is Associated With Specific Cognitive Alterations
por: Artusi, Carlo Alberto, et al.
Publicado: (2019)

Deep Brain Stimulation Outcomes in Parkinson's Disease Patients with Cognitive Impairment: Implications and Considerations
por: Romagnolo, Alberto, et al.
Publicado: (2023)

Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas
por: Hinojosa-Amaya, José Miguel, et al.
Publicado: (2020)

Endocrine disrupting chemicals: effects on pituitary, thyroid and adrenal glands
por: Egalini, Filippo, et al.
Publicado: (2022)

Impulse control disorder and response-inhibition alterations in Parkinson’s disease. A rare case of totally absent functionality of the medial-prefrontal cortex and review of literature
por: Palermo, Sara, et al.
Publicado: (2017)

End-of-Life in Oncologic Patients’ Dream Content
por: Cicolin, Alessandro, et al.
Publicado: (2020)

Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy
por: Bona, C., et al.
Publicado: (2022)

FRI305 Impulse Control Disorders In Patients With Prolactinomas And Non-Functioning Pituitary Adenomas Treated With Dopamine Agonists
por: Kolitz, Tamara, et al.
Publicado: (2023)

Assessing REM Sleep Behaviour Disorder: From Machine Learning Classification to the Definition of a Continuous Dissociation Index
por: Rechichi, Irene, et al.
Publicado: (2021)

GHRH + arginine test and body mass index: do we need to review diagnostic criteria for GH deficiency?
por: Gasco, V., et al.
Publicado: (2023)

Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson’s disease
por: Montanaro, Elisa, et al.
Publicado: (2021)

COVID-19 and Parkinson’s Disease: What Do We Know So Far?
por: Artusi, Carlo Alberto, et al.
Publicado: (2021)

SARS-CoV-2 vaccination, Parkinson’s disease, and other movement disorders: case series and short literature review
por: Imbalzano, Gabriele, et al.
Publicado: (2022)

Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment
por: Prencipe, N., et al.
Publicado: (2020)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2022)

COVID-19 in Parkinson's disease: Report on prevalence and outcome
por: Artusi, Carlo Alberto, et al.
Publicado: (2020)

Dopamine transporter blockade during adolescence increases adult dopamine function, impulsivity, and aggression
por: Suri, Deepika, et al.
Publicado: (2023)

Development and internal validation of a predictive score for the diagnosis of central adrenal insufficiency when morning cortisol is in the grey zone
por: Bioletto, F., et al.
Publicado: (2022)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

MRI Assessment of Cardiac Function and Morphology in Adult Patients With Growth Hormone Deficiency: A Systematic Review and Meta-Analysis
por: Bioletto, Fabio, et al.
Publicado: (2022)

Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic
por: Montanaro, Elisa, et al.
Publicado: (2021)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

Dopamine and reward hypersensitivity in Parkinson’s disease with impulse control disorder
por: Drew, Daniel S, et al.
Publicado: (2020)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Increased Impulsivity Retards the Transition to Dorsolateral Striatal Dopamine Control of Cocaine Seeking
por: Murray, Jennifer E., et al.
Publicado: (2014)

Publicity and reports of behavioral addictions associated with dopamine agonists
por: Gendreau, Katherine E., et al.
Publicado: (2016)

Neuroendocrine response to diclofenac in healthy subjects: a pilot study
por: Varaldo, E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g2hsqf9opncpa731tflbte9g5m